Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Stardust Power stock logo

1. Stardust Power NASDAQ:SDST

$0.50 -0.03 (-5.84%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.51 +0.00 (+0.79%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Market Capitalization
$26.66 million
Consensus Rating
Buy
Consensus Price Target
$5.11 (+912.4% Upside)
Volume
208,491 shares
Average Volume
359,297 shares
Today's Range
$0.48
$0.54
Cardiol Therapeutics stock logo

2. Cardiol Therapeutics NASDAQ:CRDL

$0.91 -0.01 (-1.09%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.93 +0.02 (+1.76%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol Therapeutics

Market Capitalization
$75.17 million
P/E Ratio
-2.33
Consensus Rating
Buy
Consensus Price Target
$8.40 (+823.1% Upside)
Volume
205,795 shares
Average Volume
383,791 shares
Reviva Pharmaceuticals stock logo

3. Reviva Pharmaceuticals NASDAQ:RVPH

$0.56 +0.00 (+0.63%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.56 +0.00 (+0.09%)
As of 05:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva Pharmaceuticals

Market Capitalization
$18.84 million
P/E Ratio
-0.51
Consensus Rating
Buy
Consensus Price Target
$10.00 (+1,674.6% Upside)
Volume
806,140 shares
Average Volume
1.09 million shares
FibroBiologics stock logo

4. FibroBiologics NASDAQ:FBLG

$0.88 -0.06 (-6.56%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.91 +0.04 (+4.46%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologics

Market Capitalization
$31.86 million
Consensus Rating
Buy
Consensus Price Target
$13.00 (+1,385.7% Upside)
Volume
197,192 shares
Average Volume
276,360 shares
Today's Range
$0.87
$0.95
PMV Pharmaceuticals stock logo

5. PMV Pharmaceuticals NASDAQ:PMVP

$1.00 -0.01 (-0.50%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$1.00 +0.01 (+0.50%)
As of 04/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. More about PMV Pharmaceuticals

Market Capitalization
$51.67 million
P/E Ratio
-1.00
Consensus Rating
Buy
Consensus Price Target
$5.50 (+452.8% Upside)
Volume
105,975 shares
Average Volume
274,313 shares
Invivyd stock logo

6. Invivyd NASDAQ:IVVD

$0.55 -0.03 (-5.03%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.55 +0.00 (+0.55%)
As of 06:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More about Invivyd

Market Capitalization
$65.98 million
P/E Ratio
-0.28
Consensus Rating
Buy
Consensus Price Target
$7.89 (+1,334.1% Upside)
Volume
1.71 million shares
Average Volume
4.22 million shares
Remove Ads
Context Therapeutics stock logo

7. Context Therapeutics NASDAQ:CNTX

$0.72 +0.04 (+5.74%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.70 -0.02 (-3.20%)
As of 05:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$64.50 million
P/E Ratio
-0.79
Consensus Rating
Buy
Consensus Price Target
$6.17 (+757.7% Upside)
Volume
2.02 million shares
Average Volume
398,411 shares
FiscalNote stock logo

8. FiscalNote NYSE:NOTE

$0.74 -0.06 (-7.26%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$0.72 -0.01 (-1.90%)
As of 05:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNote

Market Capitalization
$103.79 million
P/E Ratio
-3.34
Consensus Rating
Buy
Consensus Price Target
$2.66 (+261.9% Upside)
Volume
1.72 million shares
Average Volume
1.49 million shares
Lineage Cell Therapeutics stock logo

9. Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.42 -0.02 (-4.55%)
Closing price 04/3/2025 04:10 PM Eastern
Extended Trading
$0.42 0.00 (-0.07%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell Therapeutics

Market Capitalization
$91.98 million
P/E Ratio
-3.48
Consensus Rating
Buy
Consensus Price Target
$4.20 (+906.5% Upside)
Volume
1.14 million shares
Average Volume
1.30 million shares
Vor Biopharma stock logo

10. Vor Biopharma NYSE:VOR

$0.59 -0.04 (-6.94%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.63 +0.04 (+6.78%)
As of 04/3/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. More about Vor Biopharma

Market Capitalization
$73.66 million
P/E Ratio
-0.36
Consensus Rating
Buy
Consensus Price Target
$8.86 (+1,401.2% Upside)
Volume
341,462 shares
Average Volume
587,311 shares
Cresco Labs stock logo

11. Cresco Labs OTCMKTS:CRLBF

$0.62 -0.05 (-6.77%)
As of 04/3/2025 03:58 PM Eastern

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco Labs

Market Capitalization
$324.61 million
P/E Ratio
-3.10
Consensus Rating
Buy
Consensus Price Target
$3.00 (+383.9% Upside)
Volume
442,248 shares
Average Volume
684,663 shares
Remove Ads
Caribou Biosciences stock logo

12. Caribou Biosciences NASDAQ:CRBU

$0.78 -0.08 (-8.72%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.81 +0.02 (+2.68%)
As of 04/3/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. More about Caribou Biosciences

Market Capitalization
$73.01 million
P/E Ratio
-0.48
Consensus Rating
Buy
Consensus Price Target
$10.33 (+1,216.3% Upside)
Volume
953,794 shares
Average Volume
1.59 million shares
Inozyme Pharma stock logo

13. Inozyme Pharma NASDAQ:INZY

$0.88 -0.05 (-5.49%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.88 +0.00 (+0.17%)
As of 04/3/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. More about Inozyme Pharma

Market Capitalization
$59.51 million
P/E Ratio
-0.56
Consensus Rating
Buy
Consensus Price Target
$14.56 (+1,562.5% Upside)
Volume
388,310 shares
Average Volume
490,058 shares
Oncolytics Biotech stock logo

14. Oncolytics Biotech NASDAQ:ONCY

$0.51 -0.01 (-2.03%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.55 +0.04 (+7.42%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. More about Oncolytics Biotech

Market Capitalization
$44.25 million
P/E Ratio
-1.90
Consensus Rating
Buy
Consensus Price Target
$4.33 (+746.4% Upside)
Volume
294,649 shares
Average Volume
514,319 shares
Tenaya Therapeutics stock logo

15. Tenaya Therapeutics NASDAQ:TNYA

$0.52 -0.05 (-8.11%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.53 +0.01 (+1.92%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization
$45.54 million
P/E Ratio
-0.36
Consensus Rating
Buy
Consensus Price Target
$6.25 (+1,101.9% Upside)
Volume
3.13 million shares
Average Volume
2.18 million shares
Century Therapeutics stock logo

16. Century Therapeutics NASDAQ:IPSC

$0.46 -0.01 (-2.28%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.46 +0.00 (+0.22%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century Therapeutics

Market Capitalization
$39.50 million
P/E Ratio
-0.25
Consensus Rating
Buy
Consensus Price Target
$4.40 (+858.6% Upside)
Volume
610,520 shares
Average Volume
389,624 shares
Remove Ads
Biodesix stock logo

17. Biodesix NASDAQ:BDSX

$0.59 -0.03 (-5.26%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.00 (+0.05%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. More about Biodesix

Market Capitalization
$86.81 million
P/E Ratio
-1.52
Consensus Rating
Buy
Consensus Price Target
$2.95 (+396.0% Upside)
Volume
382,170 shares
Average Volume
295,940 shares
Nektar Therapeutics stock logo

18. Nektar Therapeutics NASDAQ:NKTR

$0.60 -0.06 (-8.88%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.00 (+0.58%)
As of 04/3/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. More about Nektar Therapeutics

Market Capitalization
$111.76 million
P/E Ratio
-0.71
Consensus Rating
Buy
Consensus Price Target
$4.92 (+718.8% Upside)
Volume
3.74 million shares
Average Volume
1.89 million shares
Cognition Therapeutics stock logo

19. Cognition Therapeutics NASDAQ:CGTX

$0.39 -0.03 (-6.51%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.38 -0.01 (-1.81%)
As of 06:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More about Cognition Therapeutics

Market Capitalization
$23.92 million
P/E Ratio
-0.40
Consensus Rating
Buy
Consensus Price Target
$7.13 (+1,745.9% Upside)
Volume
439,210 shares
Average Volume
2.49 million shares
Ovid Therapeutics stock logo

20. Ovid Therapeutics NASDAQ:OVID

$0.30 -0.04 (-11.35%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.30 0.00 (-0.13%)
As of 04/3/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$21.42 million
P/E Ratio
-0.64
Consensus Rating
Buy
Consensus Price Target
$3.03 (+906.4% Upside)
Volume
220,529 shares
Average Volume
430,927 shares
Mersana Therapeutics stock logo

21. Mersana Therapeutics NASDAQ:MRSN

$0.31 -0.03 (-9.94%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.32 +0.01 (+3.89%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More about Mersana Therapeutics

Market Capitalization
$38.15 million
P/E Ratio
-0.50
Consensus Rating
Buy
Consensus Price Target
$4.00 (+1,206.8% Upside)
Volume
2.54 million shares
Average Volume
2.42 million shares
Beyond Air stock logo

22. Beyond Air NASDAQ:XAIR

$0.25 -0.01 (-2.35%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.26 +0.01 (+4.73%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. More about Beyond Air

Market Capitalization
$16.88 million
P/E Ratio
-0.23
Consensus Rating
Buy
Consensus Price Target
$3.67 (+1,394.2% Upside)
Volume
741,342 shares
Average Volume
925,907 shares
Bitfarms stock logo

23. Bitfarms NASDAQ:BITF

$0.82 -0.04 (-4.52%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.83 +0.01 (+1.08%)
As of 06:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. More about Bitfarms

Market Capitalization
$393.58 million
P/E Ratio
-2.28
Consensus Rating
Moderate Buy
Consensus Price Target
$3.86 (+370.6% Upside)
Volume
7.78 million shares
Average Volume
28.71 million shares
Pyxis Oncology stock logo

24. Pyxis Oncology NASDAQ:PYXS

$0.94 -0.08 (-7.84%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.93 -0.01 (-0.74%)
As of 06:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. More about Pyxis Oncology

Market Capitalization
$57.90 million
P/E Ratio
-0.91
Consensus Rating
Moderate Buy
Consensus Price Target
$9.20 (+878.7% Upside)
Volume
398,227 shares
Average Volume
726,809 shares
Dragonfly Energy stock logo

25. Dragonfly Energy NASDAQ:DFLI

$0.77 -0.17 (-18.33%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$0.84 +0.08 (+9.81%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. More about Dragonfly Energy

Market Capitalization
$5.57 million
P/E Ratio
-0.19
Consensus Rating
Moderate Buy
Consensus Price Target
$10.93 (+1,323.1% Upside)
Volume
103,897 shares
Average Volume
75,451 shares